Metastatic HER2/Neu Over-Expressing Gastric Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The membrane-associated receptor known as human epidermal growth factor 2 (HER2, ERBB2) dimerizes with other HER family members to transmit extracellular signals to the intracellular RAS-MAP kinase and PI3 kinase-AKT signaling networks. Gastro-oesophageal adenocarcinoma is one type of tumor that overexpresses HER2. HER2 serves as an oncogene in cases of gastric cancer. Gastroesophageal cancer remains one of the most common cancers in the US, with an estimated incidence of about 45,820 cases in 2021. Despite the disease's declining incidence and death rate over the past ten years, the cost and burden on the healthcare system have grown significantly. HER2/neu is strongly associated with a number of aggressive cancers, most notably GC. The mainstay of treatment for advanced GEA continues to be systemic chemotherapy, which includes fluoropyrimidine and platinum-based regimens with or without HER2-targeting medications and checkpoint inhibitors.

Description

The membrane-associated receptor known as human epidermal growth factor 2 (HER2, ERBB2) dimerizes with other HER family members to transmit extracellular signals to the intracellular RAS-MAP kinase and PI3 kinase-AKT signaling networks. The gastro-oesophageal adenocarcinoma is one type of tumor that overexpresses HER2. HER2 serves as an oncogene in cases of gastric cancer. Protein overexpression is linked to genetic amplification of chromosome 17 segments that can result in tandem duplications or double-minute chromosomes. About 30% of gastric cancers of the intestinal type, 15% of tumors of the mixed type, and 5% of those of the diffuse type overexpress the HER2 gene. HER2 is usually not positive in signet rings. Approximately 30% of tumors at the cardiac/gastro-oesophageal junction and 15% of gastric cancers exhibit HER2 positivity, respectively, according to tumor location. The role of HER2 overexpression in patients with gastric cancer is becoming increasingly clear, and it has been linked to bad outcomes and a more aggressive form of the disease. As a biomarker for HER2-targeted therapies, HER2 has been proven clinically to be predictive.

Metastatic HER2/Neu Over-Expressing Gastric Cancer (Epidemiology)

Gastroesophageal cancer remains one of the most common cancers in the US, with an estimated incidence of about 45,820 cases in 2021. Despite the disease's declining incidence and death rate over the past ten years, the cost and burden on the healthcare system have grown significantly. The better outcomes and rise in costs (GEA) may have been caused by the use of targeted drugs and checkpoint inhibitors in the treatment of advanced gastroesophageal adenocarcinoma. Despite significant changes in the therapeutic landscape over the previous ten years, the prognosis for advanced gastroesophageal cancer remains poor, which emphasizes the significance of research and development for new treatments and strategies.

Metastatic HER2/Neu Over-Expressing Gastric Cancer -Current Market Size & Forecast Trends

The market for metastatic HER2/Neu over-expressing gastric cancer is currently valued at approximately USD 1.26 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 3.5%, reaching around USD 1.78 billion by 2033. This growth is driven by the increasing incidence of HER2-positive gastric cancer and the development of new targeted therapies, including antibody-drug conjugates like Enhertu, which have shown effectiveness in treating this aggressive form of cancer. The rising focus on innovative treatment options, along with advancements in healthcare infrastructure and increased awareness of gastric cancer, is expected to further propel market growth. Additionally, the approval of new drugs and combination therapies will likely enhance treatment outcomes for patients, positioning the market for significant expansion through 2035.

HER2/neu is strongly associated with a number of aggressive cancers, most notably GC. Following a successful phase III trial (ToGA), which demonstrated improved survival for HER2/neu-positive advanced GC patients, trastuzumab, an anti-HER2/neu antibody, has been approved for the treatment of gastric cancer. HER2/neu was associated with the outcomes and recurrence rates of breast cancer. The mainstay of treatment for advanced GEA continues to be systemic chemotherapy, which includes fluoropyrimidine and platinum-based regimens with or without HER2-targeting medications and checkpoint inhibitors. The foundation of all curative treatments continues to be surgery. Sadly, cutting-edge therapies like radiotherapy, chemotherapy, and surgery have little effect on advanced stomach cancer.

Report Highlights

Metastatic HER2/Neu Over-Expressing Gastric Cancer - Current Market Trends

Metastatic HER2/Neu Over-Expressing Gastric Cancer - Current & Forecasted Cases across the G8 Countries

Metastatic HER2/Neu Over-Expressing Gastric Cancer - Market Opportunities and Sales Potential for Agents

Metastatic HER2/Neu Over-Expressing Gastric Cancer - Patient-based Market Forecast to 2035

Metastatic HER2/Neu Over-Expressing Gastric Cancer - Untapped Business Opportunities

Metastatic HER2/Neu Over-Expressing Gastric Cancer - Product Positioning Vis-a-vis Competitors' Products

Metastatic HER2/Neu Over-Expressing Gastric Cancer - KOLs Insight